GB581334A
(en)
|
1943-09-29 |
1946-10-09 |
Francis Henry Swinden Curd |
New pyrimidine compounds
|
JPS4921148B1
(fr)
|
1970-12-28 |
1974-05-30 |
|
|
JPS4921149B1
(fr)
|
1970-12-28 |
1974-05-30 |
|
|
AT340933B
(de)
|
1973-08-20 |
1978-01-10 |
Thomae Gmbh Dr K |
Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
|
DE2341925A1
(de)
|
1973-08-20 |
1975-03-06 |
Thomae Gmbh Dr K |
Neue pyrimidinderivate und verfahren zu ihrer herstellung
|
US4994386A
(en)
|
1987-07-13 |
1991-02-19 |
Pharmacia Diagnostics, Inc. |
Production of HBLV virus in the HSB-2 cell line
|
US4929726A
(en)
|
1988-02-09 |
1990-05-29 |
Georgia State University Foundation, Inc. |
Novel diazines and their method of preparation
|
EP0330263A1
(fr)
|
1988-02-25 |
1989-08-30 |
Merck & Co. Inc. |
Pipérazinylalkylpyrimidines comme agents hypoglycémiques
|
GB9012311D0
(en)
|
1990-06-01 |
1990-07-18 |
Wellcome Found |
Pharmacologically active cns compounds
|
WO1992000970A1
(fr)
|
1990-07-03 |
1992-01-23 |
Mitsui Petrochemical Industries, Limited |
Compose de pyrimidine et sel pharmaceutiquement acceptable de ce compose
|
US5786355A
(en)
|
1995-04-13 |
1998-07-28 |
Taiho Pharmaceutical Co., Ltd. |
4,6-diarylpyrimidine derivatives and salts thereof
|
JP3734907B2
(ja)
|
1996-12-19 |
2006-01-11 |
富士写真フイルム株式会社 |
現像処理方法
|
EP1020462B1
(fr)
|
1997-07-24 |
2004-02-11 |
Zenyaku Kogyo Kabushiki Kaisha |
Composes heterocycliques et agent antitumoral contenant lesdits composes utilises comme ingredients actifs
|
JPH11158073A
(ja)
|
1997-09-26 |
1999-06-15 |
Takeda Chem Ind Ltd |
アデノシンa3拮抗剤
|
US6440965B1
(en)
|
1997-10-15 |
2002-08-27 |
Krenitsky Pharmaceuticals, Inc. |
Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
|
US6150362A
(en)
|
1997-12-12 |
2000-11-21 |
Henkin; Jack |
Triazine angiogenesis inhibitors
|
DK0930302T3
(da)
|
1998-01-16 |
2003-07-21 |
Hoffmann La Roche |
Benzosulfonderivater
|
JP4533534B2
(ja)
|
1998-06-19 |
2010-09-01 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
グリコーゲンシンターゼキナーゼ3のインヒビター
|
US7045519B2
(en)
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
EP1144390A2
(fr)
|
1999-01-22 |
2001-10-17 |
Amgen Inc., |
Inhibiteurs de kinase
|
US6495558B1
(en)
|
1999-01-22 |
2002-12-17 |
Amgen Inc. |
Kinase inhibitors
|
DE60006541D1
(de)
|
1999-06-30 |
2003-12-18 |
Merck & Co Inc |
Src-kinase hemmende verbindungen
|
CA2376951A1
(fr)
|
1999-06-30 |
2001-01-04 |
Peter J. Sinclair |
Composes inhibiteurs de la kinase src
|
EP1206260A4
(fr)
|
1999-06-30 |
2002-10-30 |
Merck & Co Inc |
Composes inhibiteurs de la src kinase
|
CA2379064A1
(fr)
|
1999-07-15 |
2001-01-25 |
Pharmacopeia, Inc. |
Antagonistes du recepteur b1 de la bradykinine
|
JP2001089452A
(ja)
|
1999-09-22 |
2001-04-03 |
Sankyo Co Ltd |
ピリミジン誘導体
|
CN1429222A
(zh)
|
2000-02-17 |
2003-07-09 |
安姆根有限公司 |
激酶抑制剂
|
CN100355751C
(zh)
|
2000-03-29 |
2007-12-19 |
西克拉塞尔有限公司 |
2-取代的4-杂芳基-嘧啶、其组合物及其用途
|
WO2001083456A1
(fr)
|
2000-04-27 |
2001-11-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
Derives d'heteroaryle condenses
|
MXPA02010693A
(es)
|
2000-04-28 |
2003-03-10 |
Tanabe Seiyaku Co |
Compuestos ciclicos.
|
JP2004501913A
(ja)
|
2000-06-23 |
2004-01-22 |
ブリストル−マイヤーズ スクイブ ファーマ カンパニー |
ヘテロアリール−フェニル置換Xa因子阻害剤
|
AU2001295026B2
(en)
|
2000-09-06 |
2008-04-03 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibitors of glycogen synthase kinase 3
|
CA2422371C
(fr)
|
2000-09-15 |
2010-05-18 |
Vertex Pharmaceuticals Incorporated |
Composes de pyrazole utiles comme inhibiteurs de proteine kinase
|
SE0004053D0
(sv)
|
2000-11-06 |
2000-11-06 |
Astrazeneca Ab |
N-type calcium channel antagonists for the treatment of pain
|
US20030105090A1
(en)
|
2000-12-21 |
2003-06-05 |
David Bebbington |
Pyrazole compounds useful as protein kinase inhibitors
|
WO2002062766A2
(fr)
|
2001-02-07 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes
|
WO2002064096A2
(fr)
|
2001-02-16 |
2002-08-22 |
Tularik Inc. |
Procedes d'utilisation d'agents antiviraux a base de pyrimidine
|
JP2004531571A
(ja)
|
2001-05-25 |
2004-10-14 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物
|
HUP0402352A2
(hu)
|
2001-06-19 |
2005-02-28 |
Bristol-Myers Squibb Co. |
Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
WO2003030909A1
(fr)
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
|
WO2004078163A2
(fr)
|
2003-02-28 |
2004-09-16 |
Transform Pharmaceuticals, Inc. |
Compositions pharmaceutiques a base d'un co-cristal
|
WO2003078423A1
(fr)
|
2002-03-15 |
2003-09-25 |
Vertex Pharmaceuticals, Inc. |
Compositions s'utilisant comme inhibiteurs de proteine kinases
|
US20040009981A1
(en)
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
EP1485100B1
(fr)
|
2002-03-15 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Azinylaminoazoles utilises comme inhibiteurs de proteine kinases
|
EP1485381B8
(fr)
|
2002-03-15 |
2010-05-12 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
|
US20040082627A1
(en)
|
2002-06-21 |
2004-04-29 |
Darrow James W. |
Certain aromatic monocycles as kinase modulators
|
AU2003275242B2
(en)
|
2002-09-27 |
2010-03-04 |
Merck Sharp & Dohme Corp. |
Substituted pyrimidines
|
CA2501685A1
(fr)
|
2002-10-08 |
2004-04-22 |
Massachusetts Institute Of Technology |
Composes pour la modulation du transport du cholesterol
|
US7223870B2
(en)
|
2002-11-01 |
2007-05-29 |
Pfizer Inc. |
Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
|
EP2316831B1
(fr)
|
2002-11-21 |
2013-03-06 |
Novartis AG |
Dérivés de 2-(morpholin-4-yl)pyrimidine comme inhibiteurs de Phosphotidylinositol (PI) 3-kinase pour le traitement de cancers.
|
CN101468965A
(zh)
|
2003-03-24 |
2009-07-01 |
默克公司 |
联芳基取代的6元杂环钠通道阻滞剂
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
WO2004092196A2
(fr)
|
2003-04-09 |
2004-10-28 |
Exelixis, Inc. |
Modulateurs de tie-2 et procedes d'utilisation
|
WO2005009977A1
(fr)
|
2003-07-15 |
2005-02-03 |
Neurogen Corporation |
Analogues de pyrimidine-4-ylamine substitues constituant des ligands des recepteurs vanilloides
|
AU2004257289A1
(en)
|
2003-07-16 |
2005-01-27 |
Neurogen Corporation |
Biaryl piperazinyl-pyridine analogues
|
PE20050952A1
(es)
*
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
ATE485824T1
(de)
|
2004-04-13 |
2010-11-15 |
Icagen Inc |
Polycyclische pyrimidine als kaliumionenkanal- modulatoren
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
MY145822A
(en)
|
2004-08-13 |
2012-04-30 |
Neurogen Corp |
Substituted biaryl piperazinyl-pyridine analogues
|
EP1827434B1
(fr)
*
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Heterocycles substitues et leurs procedes d'utilisation
|
CA2590299A1
(fr)
|
2004-12-13 |
2006-06-22 |
Neurogen Corporation |
Analogues de piperazinyl-pyridine
|
WO2006071538A2
(fr)
|
2004-12-13 |
2006-07-06 |
Neurogen Corporation |
Analogues de biaryle substitues
|
KR101328273B1
(ko)
|
2004-12-28 |
2013-11-14 |
키넥스 파마슈티컬즈, 엘엘씨 |
세포 증식 질환의 치료를 위한 조성물 및 방법
|
US20080124384A1
(en)
|
2005-01-19 |
2008-05-29 |
Blum Charles A |
Heteroaryl Substituted Piperazinyl-Pyridine Analogues
|
EP1877388A2
(fr)
|
2005-02-25 |
2008-01-16 |
Kudos Pharmaceuticals Ltd |
Composes d'hydrazinomethyl, d'hydrazonomethylet heterocycliques a 5 atomes en tant qu'inhibiteurs du mtor et leur utilisation comme agents anticancereux
|
WO2006113704A2
(fr)
|
2005-04-18 |
2006-10-26 |
Neurogen Corporation |
Antagonistes cb1 heteroaryle substitue
|
GB2431156A
(en)
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
US20110034454A1
(en)
|
2006-01-11 |
2011-02-10 |
Allan Paul Dishington |
Morpholino pyrimidine derivatives and their use in therapy
|
JO2660B1
(en)
*
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
WO2007120897A2
(fr)
*
|
2006-04-13 |
2007-10-25 |
The Trustees Of Columbia University In The City Of New York |
Compositions et dispositifs intraluminaux permettant d'inhiber la stenose vasculaire
|
CL2007003847A1
(es)
|
2006-12-28 |
2008-04-18 |
Basf Ag |
Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.
|
WO2008098058A1
(fr)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Inhibiteurs de la pi3-kinase et procédés de leur utilisation
|
US7957951B2
(en)
|
2007-03-16 |
2011-06-07 |
Robert Bosch Gmbh |
Address translation system for use in a simulation environment
|
CN101801962A
(zh)
|
2007-07-09 |
2010-08-11 |
阿斯利康(瑞典)有限公司 |
用于治疗增殖疾病的三取代嘧啶衍生物
|
WO2009066084A1
(fr)
|
2007-11-21 |
2009-05-28 |
F. Hoffmann-La Roche Ag |
2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3
|
ES2471452T3
(es)
|
2008-03-05 |
2014-06-26 |
Novartis Ag |
Uso de 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4-trifluorometil-piridin-2-ilamina para el tratamiento de carcinoma de pulmón de células no pequeñas con resistencia adquirida a los moduladores del receptor del factor de crecimiento epid�rmico (EGFR).
|
BRPI0909082A2
(pt)
|
2008-03-26 |
2019-02-26 |
Novartis Ag |
imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
|
JP2011515462A
(ja)
|
2008-03-27 |
2011-05-19 |
アウククランド ウニセルビセス リミテッド |
置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
|
EP2280948A1
(fr)
|
2008-04-09 |
2011-02-09 |
Mitsubishi Tanabe Pharma Corporation |
Dérivés de pyrimidine, pyridine et triazine en tant qu ouvreurs de canaux maxi-k
|
GB0815369D0
(en)
|
2008-08-22 |
2008-10-01 |
Summit Corp Plc |
Compounds for treatment of duchenne muscular dystrophy
|
AU2009309616B2
(en)
|
2008-10-31 |
2014-02-13 |
Novartis Ag |
Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
WO2010068863A2
(fr)
|
2008-12-12 |
2010-06-17 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Composés de pyrimidine et leurs procédés de fabrication et d'utilisation
|
JP5747440B2
(ja)
|
2009-02-06 |
2015-07-15 |
住友化学株式会社 |
ヒドラジド化合物及びその有害生物防除用途
|
EP2394999B1
(fr)
|
2009-02-06 |
2014-01-29 |
Nippon Shinyaku Co., Ltd. |
Dérivé d'aminopyrazine et médicament correspondant
|
US20120121515A1
(en)
|
2009-03-13 |
2012-05-17 |
Lenny Dang |
Methods and compositions for cell-proliferation-related disorders
|
WO2010120994A2
(fr)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse
|
CA2760911A1
(fr)
|
2009-05-19 |
2010-11-25 |
George E. Davis |
Composes et procedes pour lutter contre les champignons
|
EP2451802A1
(fr)
|
2009-07-07 |
2012-05-16 |
Pathway Therapeutics, Inc. |
Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation dans le traitement du cancer
|
TWI393716B
(zh)
|
2009-08-04 |
2013-04-21 |
Merck Sharp & Dohme |
作為ixa因子抑制劑之雜環化合物
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
SG179085A1
(en)
|
2009-09-09 |
2012-04-27 |
Avila Therapeutics Inc |
Pi3 kinase inhibitors and uses thereof
|
WO2011072174A1
(fr)
|
2009-12-09 |
2011-06-16 |
Agios Pharmaceuticals, Inc. |
Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh
|
GB201004200D0
(en)
|
2010-03-15 |
2010-04-28 |
Univ Basel |
Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
|
US9133123B2
(en)
|
2010-04-23 |
2015-09-15 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
US20130109643A1
(en)
|
2010-05-10 |
2013-05-02 |
The Johns Hopkins University |
Metabolic inhibitor against tumors having an idh mutation
|
BR112013001122B1
(pt)
|
2010-07-16 |
2021-06-08 |
Agios Pharmaceuticals, Inc |
composto de fórmula ii, uso do composto e composição farmacêutica compreendendo dito composto
|
BR112013007123B1
(pt)
|
2010-10-01 |
2021-11-09 |
Novartis Ag |
Forma cristalina do sal de monocloridrato de um composto a, seu uso, e composição farmacêutica
|
PT2629776T
(pt)
|
2010-10-18 |
2017-11-15 |
Cerenis Therapeutics Holding Sa |
Compostos, composições e métodos úteis para a mobilização de colesterol
|
GB201106829D0
(en)
|
2011-04-21 |
2011-06-01 |
Proximagen Ltd |
Heterocyclic compounds
|
MX2013009256A
(es)
|
2011-02-11 |
2013-12-09 |
Dana Farber Cancer Inst Inc |
Metodo para inhibir las celulas tumorales hamartoma.
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
KR20140059786A
(ko)
|
2011-09-01 |
2014-05-16 |
노파르티스 아게 |
골암의 치료에 사용하기 위한 또는 골 내로의 원발성 암 세포의 전이성 파종을 예방하기 위한 pi3k 억제제
|
AU2012313888B2
(en)
|
2011-09-27 |
2016-03-31 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
AU2012318874A1
(en)
|
2011-10-06 |
2014-05-15 |
Merck Sharp & Dohme Corp. |
1,3-substituted azetidine PDE10 inhibitors
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
US10213432B2
(en)
*
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
EP2858631A1
(fr)
|
2012-06-06 |
2015-04-15 |
Novartis AG |
Combinaison d'un inhibiteur de 17-alpha-hydroxylase (c17,20-lyase) et d'un inhibiteur spécifique de pi-3k pour le traitement d'une maladie tumorale
|
KR20210049187A
(ko)
|
2012-08-16 |
2021-05-04 |
노파르티스 아게 |
Pi3k 억제제와 c-met 억제제의 조합물
|
ES2605638T3
(es)
|
2012-10-23 |
2017-03-15 |
Novartis Ag |
Proceso Mejorado para fabricar 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
AP2015008707A0
(en)
|
2013-03-14 |
2015-09-30 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
US20160039802A1
(en)
|
2013-03-14 |
2016-02-11 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
|
CN103483345B
(zh)
|
2013-09-25 |
2016-07-06 |
中山大学 |
Pi3k激酶抑制剂、包含其的药物组合物及其应用
|
CN103694218B
(zh)
|
2013-12-05 |
2016-04-27 |
中山大学 |
嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用
|